STOCKWATCH
·
Medical/Dental Instruments
Quarterly ResultMay 6, 2026, 04:20 PM

Envista Q1 Sales $706M, EPS $0.23; Authorizes $300M Buyback

AI Summary

Envista Holdings Corporation reported strong first-quarter 2026 financial results, with sales reaching $706 million and core sales growth of 9.5% year-over-year. The company achieved a 50% increase in adjusted diluted EPS to $0.36 and a 25% rise in adjusted EBITDA to $99 million. Envista also announced an incremental $300 million share repurchase program, reaffirming its full-year 2026 guidance for core sales growth of 2% to 4% and adjusted diluted EPS of $1.35 to $1.45.

Key Highlights

  • Envista authorized a new $300 million share repurchase program through 2029.
  • Q1 2026 sales reached $706 million, with core sales growth of 9.5% YoY.
  • Adjusted diluted EPS increased 50% YoY to $0.36.
  • Adjusted EBITDA grew 25% YoY to $99 million, with a 14.0% margin.
  • Specialty Products & Technologies segment core growth was 8.4%.
  • Equipment & Consumables segment core growth was 11.5%.
  • Reaffirmed full-year 2026 guidance: core sales growth 2-4%, adjusted EPS $1.35-$1.45.
NVST
Medical/Dental Instruments
Envista Holdings Corp

Price Impact